Evaxion A/SEVAX決算レポート
Nasdaq
Evaxion A/S is a Danish clinical-stage biotechnology company that leverages proprietary artificial intelligence platforms to develop targeted immunotherapies. Its core pipeline includes personalized cancer vaccines, off-the-shelf immuno-oncology treatments, and novel infectious disease therapies, advancing programs through partnerships with global pharmaceutical stakeholders.
What changed in Evaxion A/S's 20-F — 2022 vs 2023
No meaningful paragraph-level changes detected in the compared sections. Either the two filings are nearly identical or the sections did not parse.